Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

Locally Advanced Adrenal Cortical Carcinoma · Metastatic Adrenal Cortical Carcinoma · Recurrent Adrenal Cortical Carcinoma · Stage III Adrenal Cortical Carcinoma AJCC v8 · Stage IV Adrenal Cortical Carcinoma AJCC v8 · Unresectable Adrenal Cortical Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • UC San Diego Moores Cancer Center, La Jolla, California, United States

    Contact: Study coordinator (Site Public Contact) · cancercto@ucsd.edu · 858-822-5354
    Contact: Principal Investigator (Yu-Wei Chen)
  • Valley Children's Hospital, Madera, California, United States

    Contact: Study coordinator (Site Public Contact) · Research@valleychildrens.org · 559-353-3000
    Contact: Principal Investigator (Ruetima Titapiwatanakun)
  • UCHealth University of Colorado Hospital, Aurora, Colorado, United States

    Contact: Study coordinator (Site Public Contact) · 720-848-0650
    Contact: Principal Investigator (Laura Graham)
  • Lurie Children's Hospital-Chicago, Chicago, Illinois, United States

    Contact: Study coordinator (Site Public Contact) · 773-880-4562
    Contact: Principal Investigator (Elizabeth A. Sokol)
  • Northwestern University, Chicago, Illinois, United States

    Contact: Study coordinator (Site Public Contact) · cancer@northwestern.edu · 312-695-1301
    Contact: Principal Investigator (Mary F. Mulcahy)
  • Carle at The Riverfront, Danville, Illinois, United States

    Contact: Study coordinator (Site Public Contact) · Research@Carle.com · 800-446-5532
    Contact: Principal Investigator (Priyank P. Patel)
  • Northwestern Medicine Cancer Center Kishwaukee, DeKalb, Illinois, United States

    Contact: Study coordinator (Site Public Contact) · Donald.Smith3@nm.org · 630-352-5360
    Contact: Principal Investigator (Mary F. Mulcahy)
  • Carle Physician Group-Effingham, Effingham, Illinois, United States

    Contact: Study coordinator (Site Public Contact) · Research@carle.com · 800-446-5532
    Contact: Principal Investigator (Priyank P. Patel)
  • Northwestern Medicine Cancer Center Delnor, Geneva, Illinois, United States

    Contact: Study coordinator (Site Public Contact) · Donald.Smith3@nm.org · 630-352-5360
    Contact: Principal Investigator (Mary F. Mulcahy)
  • Northwestern Medicine Glenview Outpatient Center, Glenview, Illinois, United States

    Contact: Study coordinator (Site Public Contact) · 312-695-1102
    Contact: Principal Investigator (Mary F. Mulcahy)
  • Northwestern Medicine Grayslake Outpatient Center, Grayslake, Illinois, United States

    Contact: Study coordinator (Site Public Contact) · 312-695-1102
    Contact: Principal Investigator (Mary F. Mulcahy)
  • Northwestern Medicine Lake Forest Hospital, Lake Forest, Illinois, United States

    Contact: Study coordinator (Site Public Contact) · cancertrials@northwestern.edu
    Contact: Principal Investigator (Mary F. Mulcahy)
  • Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois, United States

    Contact: Study coordinator (Site Public Contact) · Research@carle.com · 800-446-5532
    Contact: Principal Investigator (Priyank P. Patel)
  • Carle BroMenn Medical Center, Normal, Illinois, United States

    Contact: Study coordinator (Site Public Contact) · Research@Carle.com · 800-446-5532
    Contact: Principal Investigator (Priyank P. Patel)
  • Carle Cancer Institute Normal, Normal, Illinois, United States

    Contact: Study coordinator (Site Public Contact) · Research@Carle.com · 800-446-5532
    Contact: Principal Investigator (Priyank P. Patel)
  • Northwestern Medicine Oak Brook, Oak Brook, Illinois, United States

    Contact: Study coordinator (Site Public Contact) · nctnprogram_rhlccc@northwestern.edu
    Contact: Principal Investigator (Mary F. Mulcahy)
  • Northwestern Medicine Orland Park, Orland Park, Illinois, United States

    Contact: Study coordinator (Site Public Contact) · nctnprogram_rhlccc@northwestern.edu
    Contact: Principal Investigator (Mary F. Mulcahy)
  • Memorial Hospital East, Shiloh, Illinois, United States

    Contact: Study coordinator (Site Public Contact) · dschwab@wustl.edu · 314-747-9912
    Contact: Principal Investigator (Nikolaos Trikalinos)
  • Carle Cancer Center, Urbana, Illinois, United States

    Contact: Study coordinator (Site Public Contact) · Research@carle.com · 800-446-5532
    Contact: Principal Investigator (Priyank P. Patel)
  • Northwestern Medicine Cancer Center Warrenville, Warrenville, Illinois, United States

    Contact: Study coordinator (Site Public Contact) · Donald.Smith3@nm.org · 630-352-5360
    Contact: Principal Investigator (Mary F. Mulcahy)
  • UI Health Care Mission Cancer and Blood - Ankeny Clinic, Ankeny, Iowa, United States

    Contact: Study coordinator (Site Public Contact) · 515-241-3305
    Contact: Principal Investigator (Seema Harichand-Herdt)
  • Saint Anthony Regional Hospital, Carroll, Iowa, United States

    Contact: Study coordinator (Site Public Contact) · sbenson@iora.org · 515-689-7658
    Contact: Principal Investigator (Seema Harichand-Herdt)
  • UI Health Care Mission Cancer and Blood - West Des Moines Clinic, Clive, Iowa, United States

    Contact: Study coordinator (Site Public Contact) · 515-241-3305
    Contact: Principal Investigator (Seema Harichand-Herdt)
  • Iowa Methodist Medical Center, Des Moines, Iowa, United States

    Contact: Study coordinator (Site Public Contact) · 515-241-6727
    Contact: Principal Investigator (Seema Harichand-Herdt)
  • UI Health Care Mission Cancer and Blood - Des Moines Clinic, Des Moines, Iowa, United States

    Contact: Study coordinator (Site Public Contact) · 515-241-3305
    Contact: Principal Investigator (Seema Harichand-Herdt)
  • Broadlawns Medical Center, Des Moines, Iowa, United States

    Contact: Study coordinator (Site Public Contact) · 515-282-2200
    Contact: Principal Investigator (Seema Harichand-Herdt)
  • Mercy Medical Center - Des Moines, Des Moines, Iowa, United States

    Contact: Study coordinator (Site Public Contact) · 515-241-3305
    Contact: Principal Investigator (Richard L. Deming)
  • UI Health Care Mission Cancer and Blood - Laurel Clinic, Des Moines, Iowa, United States

    Contact: Study coordinator (Site Public Contact) · 515-241-3305
    Contact: Principal Investigator (Seema Harichand-Herdt)
  • UI Healthcare Mission Cancer and Blood - Fort Dodge, Fort Dodge, Iowa, United States

    Contact: Study coordinator (Site Public Contact) · trials@missioncancer.com · 515-282-2921
    Contact: Principal Investigator (Seema Harichand-Herdt)
  • UI Health Care Mission Cancer and Blood - Waukee Clinic, Waukee, Iowa, United States

    Contact: Study coordinator (Site Public Contact) · 515-241-3305
    Contact: Principal Investigator (Seema Harichand-Herdt)
  • Dana-Farber Cancer Institute, Boston, Massachusetts, United States

    Contact: Study coordinator (Site Public Contact) · 877-442-3324
    Contact: Principal Investigator (Stephanie A. Berg)
  • University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States

    Contact: Study coordinator (Site Public Contact) · CancerAnswerLine@med.umich.edu · 800-865-1125
    Contact: Principal Investigator (Francis P. Worden)
  • Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters, Missouri, United States

    Contact: Study coordinator (Site Public Contact) · info@siteman.wustl.edu · 800-600-3606
    Contact: Principal Investigator (Nikolaos Trikalinos)
  • Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri, United States

    Contact: Study coordinator (Site Public Contact) · info@siteman.wustl.edu · 800-600-3606
    Contact: Principal Investigator (Nikolaos Trikalinos)
  • Children's Mercy Hospitals and Clinics, Kansas City, Missouri, United States

    Contact: Study coordinator (Site Public Contact) · COGResearchGroup@cmh.edu · 816-302-6808
    Contact: Principal Investigator (Keith J. August)
  • CoxHealth South Hospital, Springfield, Missouri, United States

    Contact: Study coordinator (Site Public Contact) · 417-269-4520
    Contact: Principal Investigator (Jay W. Carlson)
  • Washington University School of Medicine, St Louis, Missouri, United States

    Contact: Study coordinator (Site Public Contact) · info@siteman.wustl.edu · 800-600-3606
    Contact: Principal Investigator (Nikolaos Trikalinos)
  • Siteman Cancer Center-South County, St Louis, Missouri, United States

    Contact: Study coordinator (Site Public Contact) · info@siteman.wustl.edu · 800-600-3606
    Contact: Principal Investigator (Nikolaos Trikalinos)
  • Siteman Cancer Center at Christian Hospital, St Louis, Missouri, United States

    Contact: Study coordinator (Site Public Contact) · info@siteman.wustl.edu · 800-600-3606
    Contact: Principal Investigator (Nikolaos Trikalinos)
  • Nebraska Medicine-Bellevue, Bellevue, Nebraska, United States

    Contact: Study coordinator (Site Public Contact) · unmcrsa@unmc.edu · 402-559-6941
    Contact: Principal Investigator (Apar Kishor Ganti)
  • Nebraska Medicine-Village Pointe, Omaha, Nebraska, United States

    Contact: Study coordinator (Site Public Contact) · 402-559-5600
    Contact: Principal Investigator (Apar Kishor Ganti)
  • University of Nebraska Medical Center, Omaha, Nebraska, United States

    Contact: Study coordinator (Site Public Contact) · unmcrsa@unmc.edu · 402-559-6941
    Contact: Principal Investigator (Apar Kishor Ganti)
  • Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States

    Contact: Study coordinator (Site Public Contact) · 212-639-7592
    Contact: Principal Investigator (Nitya P. Raj)
  • Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States

    Contact: Study coordinator (Site Public Contact) · 212-639-7592
    Contact: Principal Investigator (Nitya P. Raj)
  • Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States

    Contact: Study coordinator (Site Public Contact) · 212-639-7592
    Contact: Principal Investigator (Nitya P. Raj)
  • Memorial Sloan Kettering Commack, Commack, New York, United States

    Contact: Study coordinator (Site Public Contact) · 212-639-7592
    Contact: Principal Investigator (Nitya P. Raj)
  • Memorial Sloan Kettering Westchester, Harrison, New York, United States

    Contact: Study coordinator (Site Public Contact) · 212-639-7592
    Contact: Principal Investigator (Nitya P. Raj)
  • Memorial Sloan Kettering Cancer Center, New York, New York, United States

    Contact: Study coordinator (Site Public Contact) · 212-639-7592
    Contact: Principal Investigator (Nitya P. Raj)
  • Memorial Sloan Kettering Nassau, Uniondale, New York, United States

    Contact: Study coordinator (Site Public Contact) · 212-639-7592
    Contact: Principal Investigator (Nitya P. Raj)
  • Duke Cancer Center Cary, Cary, North Carolina, United States

    Contact: Study coordinator (Site Public Contact) · NCTNStudyTeam@dm.duke.edu
    Contact: Principal Investigator (Diane L. Reidy-lagunes)
  • Duke University Medical Center, Durham, North Carolina, United States

    Contact: Study coordinator (Site Public Contact) · 888-275-3853
    Contact: Principal Investigator (Diane L. Reidy-lagunes)
  • Duke Cancer Center Raleigh, Raleigh, North Carolina, United States

    Contact: Study coordinator (Site Public Contact) · NCTNStudyTeam@dm.duke.edu
    Contact: Principal Investigator (Diane L. Reidy-lagunes)
  • Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

    Contact: Study coordinator (Site Public Contact) · Jamesline@osumc.edu · 800-293-5066
    Contact: Principal Investigator (Bhavana Konda)
  • University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States

    Contact: Study coordinator (Site Public Contact) · ou-clinical-trials@ouhsc.edu · 405-271-8777
    Contact: Principal Investigator (Adanma Anji Ayanambakkam Attanathi)
  • Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States

    Contact: Study coordinator (Site Public Contact) · jean.tersak@chp.edu · 412-692-8570
    Contact: Principal Investigator (Brittani K. Seynnaeve)
  • Prisma Health Cancer Institute - Spartanburg, Boiling Springs, South Carolina, United States

    Contact: Study coordinator (Site Public Contact) · Kim.Williams3@prismahealth.org · 864-522-4317
    Contact: Principal Investigator (Aniket Saha)
  • Prisma Health Richland Hospital, Columbia, South Carolina, United States

    Contact: Study coordinator (Site Public Contact) · Kim.Williams3@prismahealth.org · 864-522-4317
    Contact: Principal Investigator (Aniket Saha)
  • Prisma Health Cancer Institute - Easley, Easley, South Carolina, United States

    Contact: Study coordinator (Site Public Contact) · Kim.Williams3@prismahealth.org · 864-522-4317
    Contact: Principal Investigator (Aniket Saha)
  • BI-LO Charities Children's Cancer Center, Greenville, South Carolina, United States

    Contact: Study coordinator (Site Public Contact) · Kim.Williams3@prismahealth.org · 864-522-4317
    Contact: Principal Investigator (Aniket Saha)
  • Prisma Health Cancer Institute - Butternut, Greenville, South Carolina, United States

    Contact: Study coordinator (Site Public Contact) · Kim.Williams3@prismahealth.org · 864-522-4317
    Contact: Principal Investigator (Aniket Saha)
  • Prisma Health Cancer Institute - Faris, Greenville, South Carolina, United States

    Contact: Study coordinator (Site Public Contact) · Kim.Williams3@prismahealth.org · 864-522-4317
    Contact: Principal Investigator (Aniket Saha)
  • Prisma Health Cancer Institute - Eastside, Greenville, South Carolina, United States

    Contact: Study coordinator (Site Public Contact) · Kim.Williams3@prismahealth.org · 864-522-4317
    Contact: Principal Investigator (Aniket Saha)
  • Prisma Health Cancer Institute - Greer, Greer, South Carolina, United States

    Contact: Study coordinator (Site Public Contact) · Kim.Williams3@prismahealth.org · 864-522-4317
    Contact: Principal Investigator (Aniket Saha)
  • Prisma Health Cancer Institute - Seneca, Seneca, South Carolina, United States

    Contact: Study coordinator (Site Public Contact) · Kim.Williams3@prismahealth.org · 864-522-4317
    Contact: Principal Investigator (Aniket Saha)
  • Saint Jude Children's Research Hospital, Memphis, Tennessee, United States

    Contact: Study coordinator (Site Public Contact) · referralinfo@stjude.org · 888-226-4343
    Contact: Principal Investigator (Catherine G. Lam)
  • Dell Children's Medical Center of Central Texas, Austin, Texas, United States

    Contact: Study coordinator (Site Public Contact) · TXAUS-DL-SFCHemonc.research@ascension.org · 512-628-1902
    Contact: Principal Investigator (Shannon M. Cohn)
  • Children's Hospital of San Antonio, San Antonio, Texas, United States

    Contact: Study coordinator (Site Public Contact) · bridget.medina@christushealth.org · 210-704-2894
    Contact: Principal Investigator (Julie Voeller)
  • University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States

    Contact: Study coordinator (Site Public Contact) · phoresearchoffice@uthscsa.edu · 210-450-3800
    Contact: Principal Investigator (Aaron J. Sugalski)
  • VCU Massey Cancer Center at Stony Point, Richmond, Virginia, United States

    Contact: Study coordinator (Site Public Contact) · ctoclinops@vcu.edu
    Contact: Principal Investigator (Asit K. Paul)
  • VCU Massey Comprehensive Cancer Center, Richmond, Virginia, United States

    Contact: Study coordinator (Site Public Contact) · CTOclinops@vcu.edu · 804-628-6430
    Contact: Principal Investigator (Asit K. Paul)
  • Fred Hutchinson Cancer Center, Seattle, Washington, United States

    Contact: Study coordinator (Site Public Contact) · 800-804-8824
    Contact: Principal Investigator (Keith D. Eaton)
Study leads
  • Bhavana Konda

    Principal Investigator

    Alliance for Clinical Trials in Oncology